Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Lubiprostone is a prostaglandin derivative used to treat constipation caused by irritable bowel syndrome and opioid-use. Lubiprostone is a medication used in the management of idiopathic chronic constipation.
- Mechanism
- Curator reviewed
Lubiprostone acts by specifically activating ClC-2 chloride channels, which is a normal constituent of the apical membrane of the human intestine, in a protein kinase A action independent fashion. Activation of ClC-2 chloride channels causes an efflux of chloride ions into the lumen, which in turn leads to an efflux of sodium ions through a paracellular pathway to maintain isoelectric neutrality. As a result, water follows sodium into the lumen in order to maintain isotonic equilibrium, thereby increasing intestinal fluid secretion. By increasing intestinal fluid secretion, lubiprostone increases motility in the intestine, thereby increasing the passage of stool and alleviating symptoms associated with chronic idiopathic constipation. Activation of ClC-2 chloride channels may also stimulate the recovery of muscosal barrier function by restoring tight junction protein complexes in the intestine. Patch clamp cell studies in human cell lines have indicated that the majority of the beneficial biological activity of lubiprostone and its metabolites is observed only on the apical (luminal) portion of the gastrointestinal epithelium.
- Primary indication
- Lubiprostone is indicated for the treatment of adult patients with chronic idiopathic constipation, or opioid-induced constipation in patients with chronic non-cancer pain.Curator reviewed · 3 structured indications
- Formula / weight
- C20H32F2O5 · 390.468 g/mol (avg)
- First approval
- Canada, 2015 · United States, 2006
- Code names
- RU-0211
- Brand names
- Amitiza
Resolves to
WGFOBBZOWHGYQH-MXHNKVEKSA-NSMILES[H][C@@]12CC(=O)[C@H](CCCCCCC(O)=O)[C@@]1([H])CC[C@@](O)(O2)C(F)(F)CCCCWhat you can answer from here — as of October 01, 2026
Which drugs share a target with Lubiprostone, and which of those have an active Phase 3 trial?